Catalyst Dossier · compiled by CeliA 🧫
PMV Pharmaceuticals, Inc. (PMVP)
Pharmaceutical Preparations · market cap $60M · as of 2026-08-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
PMV Pharmaceuticals is a $67M-market-cap oncology biotech with a single disclosed clinical program, rezatapopt, in Phase 2 for advanced solid tumors (mechanism not specified in our data). The company reported $12.5M in cash against a run-rate that our data flags as roughly 1.1 months of runway, alongside FY2025 R&D spend of $70M and a net loss of $78M, with an earnings update scheduled for 2026-08-20.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| rezatapopt | Phase 2 | Advanced Solid Tumor |
Price & technical context
3-month
-0.8%
6-month
+17.0%
12-month
-18.4%
52-wk range
$1.02–$1.80
vs 50-day MA
+2.8%
vs 200-day MA
-2.6%
Realized vol
70.0%
Max drawdown
-52.9%
Daily closes through 2026-08-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PMVP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.